Scarica l'app Stockscreener
2.22
0.45%
-0.010
Dopo l'orario di chiusura:
2.22
Precedente Chiudi:
$2.23
Aprire:
$2.21
Volume 24 ore:
393.94K
Relative Volume:
0.35
Capitalizzazione di mercato:
$327.16M
Reddito:
$72,500
Utile/perdita netta:
$-45.96M
Rapporto P/E:
-3.258
EPS:
-0.6814
Flusso di cassa netto:
$-44.56M
1 W Prestazione:
-0.45%
1M Prestazione:
+24.72%
6M Prestazione:
+142.52%
1 anno Prestazione:
+41.40%
Intervallo 1D:
$2.16
$2.3767
Intervallo di 1 settimana:
$2.09
$2.3767
Portata 52W:
$0.7984
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
2.22 | 297.68M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-02-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-04-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-01-29 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-10 | Iniziato | Credit Suisse | Outperform |
| 2018-07-13 | Iniziato | BMO Capital Markets | Outperform |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-28 | Iniziato | SunTrust | Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Inflarx Nv Borsa (IFRX) Ultime notizie
Farallon Capital Management Acquires New Position in InflaRx NV (IFRX) - GuruFocus
InflaRx (IFRX) Latest: Ends Down by 4.72% at $2.02 in the Latest Reading; Next Test: Price Remains Between $1.92 Support and $2.12 ResistanceLarge Cap Trends - vinanet.vn
InflaRx Announces Participation in September Investor Conferences - GlobeNewswire
Commodore Capital reports 5%+ stake in InflaRx (IFRX) - Stock Titan
IFRX Q2 2026 Earnings: Wider-than-Expected Loss Raises Stakes for Clinical ExecutionMargin Guidance - Vinanet
InflaRx (IFRX) investors report 15.6% and 12.5% stakes in updated 13G/A - Stock Titan
Sirenia Capital (IFRX) discloses 8.9M InflaRx shares, a 6.1% ownership stake - Stock Titan
InflaRx (IFRX): Farallon group reports 3.33M-share, 2.3% beneficial stake - Stock Titan
EDGAR Filing Documents for 0001140361-26-033149 - SEC.gov
InflaRx N.V. SEC Filing (Aug 13, 2026) - Stock Titan
Here's Why We're Not At All Concerned With InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
IFRX Q2 2026 Earnings: EPS Misses by 51.26% Yet Shares Advance 6.52%Earnings Sentiment Score - vinanet.vn
HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - marketbeat.com
Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00 - MarketBeat
InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC and Abigail Johnson (IFRX) disclose 5.5% Inflarx stake in Schedule 13G - Stock Titan
InflaRx NV reports results for the quarter ended June 30Earnings Summary - TradingView
InflaRx N.V. (IFRX) sets up $250M shelf for stock, debt and warrants - Stock Titan
IFRX: Advanced pipeline in AAV and renal diseases, with strong funding and reduced net loss - TradingView
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K - TipRanks
InflaRx Q2 2026 earnings: Lower costs narrow the operating loss - TradingKey
InflaRx (Nasdaq: IFRX) raises $140m, funds C5a pipeline into 2029 - Stock Titan
InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases - Quiver Quantitative
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - Yahoo! Finance Canada
IFRX Q2'26 Earnings: EPS estimate is (0.07) USD - TradingView
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
InflaRx NV expected to post a loss of 6 cents a shareEarnings Preview - TradingView
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - sharewise.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline FocusNext Quarter Guidance - vinanet.vn
InflaRx N.V. Revenue Breakdown – NASDAQ:IFRX - TradingView
No Conference Call Planned for InflaRx's Aug. 6 Results - stocktitan.net
IFRX Q2'26 Earnings: revenue estimate is 6.40K USD - TradingView
InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx (NASDAQ:IFRX) Trading Down 2.3%Time to Sell? - MarketBeat
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey
IFRX|InflaRx NV|Price:1.690|Chg%:-0.050 - TradingKey
InflaRx N.V. (IFRX) Q1 2026 Earnings: Narrower Loss Beats Expectations, No Revenue Reported - vinanet.vn
TradingKey - TradingKey
InflaRx N.V. Revenue Breakdown – BOATS:IFRX - TradingView
InflaRx NV (IFRX) Cash Flow - TradingKey
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IFRX Q1 2026 Earnings: Beats EPS Estimates Despite No Revenue, Pipeline Progress Drives Stock Up 1.92%Buyback Announcement Report - vinanet.vn
IFRX Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Pipeline AdvancesEarnings Revision Report - vinanet.vn
InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key SupportAlgorithmic Stock Picks - dars.gov.et
Inflarx Nv Azioni (IFRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):